Brought to you by 
Cardiome enters $68mm anti-arrhythmic deal with Fujisawa; ends
16 Sep 2015
Executive Summary
Cardiovascular disease company Cardiome Pharma and Fujisawa Healthcare have entered into an agreement to co-develop an intravenous formulation of Cardiome's Phase III RSD1235 anti-arrhythmic drug candidate. The deal could be worth up to $68mm ($Cdn90mm).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cardiome enters $68mm anti-arrhythmic deal with Fujisawa; ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice